The Cooper Companies, Inc. (COO) DCF Valuation
TGM's two-stage DCF values The Cooper Companies, Inc. (COO) between $17.78 and $42.32 depending on assumptions, with a base case of $27.60. Growth is taken from the company's own record (blend of 5-year revenue and FCF growth), fading to 2.5% long-run; the discount rate (8.5%) reflects its beta.
What would today's price require?
$67.88 is justified only if free cash flow grows about +25.6% a year (fading to 2.5% long-run) at a 8.5% required return — faster than the company has actually grown.
| Scenario | FCF growth (fading to 2.5%) | Discount | Value / share |
|---|---|---|---|
| Conservative | 5.2%/yr | 9.5% | $17.78 |
| Base case | 8.2%/yr | 8.5% | $27.60 |
| Optimistic | 11.2%/yr | 7.5% | $42.32 |
| Analyst DCF (FMP) | independent reference — different model | $58.78 | |
Current Price
$67.88
Market-Implied Growth
+25.6%/yr
vs +6.6% 5Y actual
Model Scenario Range
$17.78 – $42.32
model output — not a price target
COO DCF Fair Value Calculator
Edit the assumptions to see how they change the estimated fair value. Opens seeded with TGM's data-driven base case for COO (growth from its own 5-year record, discount from its beta), so the sandbox starts where the scenarios above leave off. Illustrative model — not investment advice.
Base inputs: FCF $360.9M · 0.20B shares · net debt $2.4B
Estimated Fair Value
$36.51
-46.2% vs $67.88
Sensitivity — fair value by discount rate × terminal growth
How the estimated fair value shifts with the discount rate (WACC) and terminal growth, holding your 8.2%/yr FCF growth and 10-year horizon fixed. Green = above today's $67.88; red = below. Your current case is outlined.
| WACC ↓ / Terminal → | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
|---|---|---|---|---|---|
| 6.5% | $51.76 | $56.89 | $63.30 | $71.55 | $82.54 |
| 7.5% | $40.12 | $43.34 | $47.20 | $51.91 | $57.81 |
| 8.5% | $31.86 | $34.01 | $36.51 | $39.47 | $43.02 |
| 9.5% | $25.71 | $27.21 | $28.92 | $30.90 | $33.20 |
| 10.5% | $20.96 | $22.04 | $23.26 | $24.64 | $26.22 |
About The Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Albert G. White